{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.004","statisticalMethod":"Fisher Exact"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.066","upperLimit":"0.183","value":"0.115"},{"groupId":"OG001","lowerLimit":"0.209","upperLimit":"0.367","value":"0.283"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"99"}],"units":"Participants"}],"description":"Major erythroid response is defined as transfusion-independence for ≥ 8 consecutive weeks for patients who were red blood cell transfusion-dependent at baseline AND a ≥ 1 g/dL hemoglobin rise compared to mean pre-transfusion baseline value; or a \\> 2 g/dL rise in hemoglobin without transfusion for non-transfusion dependent patients.","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients receive lenalidomide PO QD on days 1-21.","id":"OG000","title":"Arm A (Lenalidomide; Randomization)"},{"description":"Patients receive lenalidomide PO QD on days 1-21 and epoetin alfa SC once weekly.","id":"OG001","title":"Arm B (Lenalidomide + Epoetin Alfa; Randomization)"}],"paramType":"NUMBER","populationDescription":"Evaluable patients randomized to either arm A or arm B","reportingStatus":"POSTED","timeFrame":"Assessed after completion of 16 weeks of treatment","title":"Proportion of Patients With Major Erythroid Response (MER)","type":"PRIMARY","unitOfMeasure":"proportion of participants"}